Therapeutic Silencing of KRAS using Systemically Delivered siRNAs

Despite being amongst the most common oncogenes in human cancer, to date there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS mutated cancer models. We identified KRAS siRNA sequences with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Main Authors: Pecot, Chad V., Wu, Sherry Y., Bellister, Seth, Filant, Justyna, Rupaimoole, Rajesha, Hisamatsu, Takeshi, Bhattacharya, Rajat, Maharaj, Anshumaan, Azam, Salma, Rodriguez-Aguayo, Cristian, Nagaraja, Archana S., Morelli, Maria Pia, Gharpure, Kshipra M., Waugh, Trent A., Gonzalez-Villasana, Vianey, Zand, Behrouz, Dalton, Heather J., Kopetz, Scott, Lopez-Berestein, Gabriel, Ellis, Lee M., Sood, Anil K.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4416486/
https://ncbi.nlm.nih.gov/pubmed/25281617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0074
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares